Aurobindo Pharma’s subsidiary, Helix Healthcare B.V., will acquire an additional 20% ownership in Luoxin Aurovitas Pharma (Chengdu) Co. Ltd from Shandong Luoxin. The agreement, finalized on December 22, 2025, increases Helix’s stake in the joint venture. The initial investment is USD 5.125 million, with potential for further stake acquisition. The deal aims to expand manufacturing capabilities and cater to growing market demand.
Increased Ownership in Luoxin Aurovitas
Aurobindo Pharma is set to increase its stake in Luoxin Aurovitas Pharma (Chengdu) Co. Ltd, a Chinese joint venture, through its subsidiary, Helix Healthcare B.V. The agreement was reached on December 22, 2025 with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., the current joint venture partner.
Transaction Details
Helix Healthcare B.V. will acquire an additional 20% ownership in Luoxin Aurovitas. The initial acquisition cost is USD 5.125 million. This will increase Helix’s ownership, with the possibility of acquiring the remaining 50% by December 2029 for USD 18.86 million, subject to certain conditions.
Strategic Rationale
The acquisition aims to expand manufacturing capabilities, specifically by adding two high-speed production lines, in order to meet increasing market demand. Luoxin Aurovitas is focused on manufacturing inhalation products. The company registered a turnover of USD 2.34 million during FY 2024-25, and its net worth was USD 15.29 million as of September 30, 2025.
Luoxin Aurovitas Background
Luoxin Aurovitas was established on March 25, 2019, as a joint venture focused on manufacturing inhalation products in China.
Source: BSE